Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma

被引：3
|
作者：
Nordstrom, Beth L. [1 ]
Hamilton, Melissa [2 ]
Collins, Jenna M. [1 ]
Earle, Dennis [2 ]
Zhang, Ying [2 ]
Srivastava, Shivani [2 ]
Hernandez-Aya, Leonel [3 ]
机构：
[1] Evidera, 500 Totten Pond Rd,Fifth Floor, Waltham, MA 02451 USA
[2] Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648 USA
[3] Washington Univ, Div Oncol, 660 South Euclid Ave, St Louis, MO 63110 USA
来源：
FUTURE ONCOLOGY | 2022年 / 18卷 / 11期
关键词：
cancer progression; immunotherapy; melanoma; survival; treatment patterns; NIVOLUMAB; IPILIMUMAB; BRAF;
D O I：
10.2217/fon-2021-0340
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Anti-PD-1-based therapies prolong survival in advanced melanoma, but disease progression is common. This study evaluated treatment patterns and overall survival (OS) after anti-PD-1 progression. Methods: Retrospective data from patients with advanced melanoma and progression on anti-PD-1 treatment between 2014 and 2019 were taken from Flatiron Health, which reflects largely community practice. Treatment patterns and OS were analyzed for BRAF mutant (mt) and wild-type (wt) subgroups; OS was also examined across all patients. Results: Progression following anti-PD-1 was recorded for 679 patients. Median OS ranged from 5.0 to 11.3 months. Of 275 BRAFmt and 374 BRAFwt patients, 113 (41.1%) and 228 (61.0%) received no subsequent therapy, respectively. However, 48.4% of BRAFmt and 57.8% of BRAFwt patients continued anti-PD-1 treatment beyond progression. Conclusion: This real-world study underscores the need for effective treatments for advanced melanoma post-progression on anti-PD-1 therapy.
引用
收藏
页码：1343 / 1355
页数：13
相关论文
共 50 条
  • [1] Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma
    Aya, Francisco
    Gaba, Lydia
    Victoria, Ivan
    Fernandez-Martinez, Aranzazu
    Tosca, Monica
    Prat, Aleix
    Arance, Ana
    FUTURE ONCOLOGY, 2016, 12 (23) : 2683 - 2688
  • [2] Outcomes after progression of disease with anti-PD-1/PDL1 therapy for advanced melanoma
    Patrinely, James R.
    Wang, Laura X.
    Davis, Elizabeth J.
    Johnson, Douglas B.
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma
    Patrinely, James R., Jr.
    Baker, Laura X.
    Davis, Elizabeth J.
    Song, Haocan
    Ye, Fei
    Johnson, Douglas B.
    CANCER, 2020, 126 (15) : 3448 - 3455
  • [4] Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
    Jansen, Y. J. L.
    Rozeman, E. A.
    Mason, R.
    Goldinger, S. M.
    Foppen, M. H. Geukes
    Hoejberg, L.
    Schmidt, H.
    van Thienen, J., V
    Haanen, J. B. A. G.
    Tiainen, L.
    Svane, I. M.
    Makela, S.
    Seremet, T.
    Arance, A.
    Dummer, R.
    Bastholt, L.
    Nyakas, M.
    Straume, O.
    Menzies, A. M.
    Long, G., V
    Atkinson, V
    Blank, C. U.
    Neyns, B.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1154 - 1161
  • [5] MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma
    Nakahara, Satoshi
    Fukushima, Satoshi
    Okada, Etsuko
    Morinaga, Jun
    Kubo, Yosuke
    Tokuzumi, Aki
    Matsumoto, Sayaka
    Tsuruta-Kadohisa, Mina
    Kimura, Toshihiro
    Kuriyama, Haruka
    Miyashita, Azusa
    Kajihara, Ikko
    Jinnin, Masatoshi
    Ihn, Hironobu
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2020, 97 (01) : 77 - 79
  • [6] Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma
    Lee, Jenny H. J.
    Lyle, Megan
    Menzies, Alexander M.
    Chan, Matthew M. K.
    Lo, Serigne
    Clements, Arthur
    Carlino, Matteo S.
    Kefford, Richard F.
    Long, Georgina, V
    PIGMENT CELL & MELANOMA RESEARCH, 2018, 31 (03) : 404 - 410
  • [7] Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy.
    Hernandez-Aya, Leonel Fernando
    Burke, Matthew
    Collins, Jenna M.
    Earle, Dennis
    Hamilton, Melissa
    Nordstrom, Beth L.
    Zhang, Ying
    Srivastava, Shivani
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Intracranial outcomes with ipilimumab and nivolumab in melanoma brain metastases following progression on anti-PD-1 therapy
    Lochrin, Sarah E.
    Kalvin, Hannah L.
    Smithy, James William
    Momtaz, Parisa
    Shoushtari, Alexander Noor
    Panageas, Katherine
    Postow, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Babacan, Nalan Akgul
    Eroglu, Zeynep
    CURRENT ONCOLOGY REPORTS, 2020, 22 (04)
  • [10] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Nalan Akgul Babacan
    Zeynep Eroglu
    Current Oncology Reports, 2020, 22
12345